Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial
Marina Shestakova,Boris Kvasnikov,Ekaterina Erina,Elena Isachenko,Alexander Andreev,study investigators,Diana Alpenidze,Alexander Ametov,Olga Demicheva,Irina Dvoryashina,Polina Ermakova,Olga Ershova,Elena Grineva,Yuriy Khalimov,Ludmila Kvitkova,Anatoliy Kuzin,Olga Lantseva,Nina Leonova,Tatiana Lysenko,Tatiana Markova,Ashot Mkrtumyan,Nina Nosova,Natalia Osokina,Leonid Pimenov,Larisa Rogova,Ludmila Ruyatkina,Oksana Rymar,Olesya Shabelnikova,Elena Smirnova,Olga Smirnova,Alexander Sobolev,Leonid Strongin,Ludmila Suplotova,Andrey Verbovoy,Anna Volkova,Alsu Zalevskaya,Olga Zanozina,Elena Zhdanova,Larisa Zhukova
DOI: https://doi.org/10.1136/bmjdrc-2022-003290
Abstract:Introduction: Most data demonstrating the efficacy and safety of luseogliflozin (luseo) in people with type 2 diabetes mellitus (T2DM) originate from the Japanese population. This study evaluated luseo versus placebo (PCB) as add-on to metformin in a Caucasian population with inadequately controlled T2DM. Research design and methods: This was a multicenter, randomized, double-blind, PCB-controlled, parallel-group study. Patients aged 18-75 years with inadequately controlled T2DM (glycated hemoglobin (HbA1c) ≥7% to ≤10% (≥53 to ≤86 mmol/mol)) despite a diet and exercise program and on a stable metformin regimen were eligible. Patients were randomized to one of three luseo groups (2.5, 5.0 and 10.0 mg) or PCB for 12 weeks (W12). The primary endpoint was change in HbA1c expressed as least-square means from baseline (W0) to W12. Results: A total of 328 patients were randomized: PCB (n=83) and luseo 2.5 mg (n=80), 5.0 mg (n=86), and 10.0 mg (n=79). Mean age (±SD) was 58.5±8.8 years; 64.6% were women; body mass index was 31.5±3.4 kg/m2; and HbA1c was 8.54±0.70. At W12, mean reductions in HbA1c from W0 were -0.98%, -1.09%, -1.18%, and -0.73% in the luseo 2.5, 5.0 and 10.0 mg, and PCB groups, respectively, all of which were statistically significant. Compared with PCB, HbA1c levels were significantly decreased by 0.25% (p=0.045), 0.36% (p=0.006), and 0.45% (p=0.001) in the luseo 2.5, 5.0, and 10.0 mg groups, respectively. In all luseo dose groups, reductions in body weight were statistically significant compared with PCB. Data from the safety analysis were consistent with the known luseo safety profile. Conclusions: All doses of luseo as add-on to metformin in Caucasian patients with uncontrolled T2DM demonstrated significant efficacy in decreasing HbA1c after W12 of treatment. Trial registration number: ISRCTN39549850.